Paratek goes 3-for-3 in PhI­II, but an­tibi­ot­ic stum­bles on side ef­fect pro­file

Paratek’s an­tibi­ot­ic omada­cy­cline has now gone three for three in Phase III — set­ting up a pitch to the FDA — but the da­ta on an oral ver­sion of the an­tibi­ot­ic had some trou­bling side ef­fects, rais­ing new ques­tions about its po­ten­tial.

On the ef­fi­ca­cy side oral omada­cy­cline looked sol­id for acute bac­te­r­i­al skin and skin struc­ture in­fec­tions (AB­SS­SI), com­ing in non­in­fe­ri­or to line­zol­id with an 87.5% re­sponse rate for their an­tibi­ot­ic against 82.5% for the in­dus­try stan­dard.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.